Business Context and Reporting Period
This Form 8-K filing covers events occurring on June 30, 2016, for Zafgen, Inc. (Note: The input metadata references "Larimar Therapeutics, Inc.", but the filing text explicitly identifies the registrant as Zafgen, Inc.). The report details the results of the Company's Annual Meeting of Stockholders and the execution of new executive compensation agreements.
Key Financial Metrics
The filing text does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and executive compensation matters.
Material Changes and Corporate Actions
Annual Meeting Results
As of the record date (May 2, 2016), there were 27,272,261 outstanding shares of common stock. Stockholders approved two proposals:
- Proposal 1: Election of Class II directors Peter Barrett, Ph.D., Frances K. Heller, and Bruce Booth, Ph.D., for three-year terms expiring in 2019.
- Proposal 2: Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2016.
Executive Compensation Agreements
On June 30, 2016, the Company entered into new severance and change in control agreements with five executive officers: Thomas E. Hughes (CEO), Patrick Loustau (President), Alicia Secor (CCO), Patricia L. Allen (CFO), and Dennis Kim (CMO). These agreements supersede prior terms.
- CEO (Dr. Hughes): Entitled to 12 months of base salary and COBRA benefits for termination without cause or for good reason. In the event of a change in control followed by such termination, benefits increase to 18 months, with immediate acceleration of all stock options.
- Other Executives: Entitled to 9 months of base salary and COBRA benefits for termination without cause or for good reason. In the event of a change in control followed by such termination, benefits increase to 12 months, with immediate acceleration of all stock options.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, or specific risk factors beyond the standard definitions of "cause," "good reason," and "change in control" within the new executive agreements. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Verify the exact vote counts for the director elections and auditor ratification against the Definitive Proxy Statement filed on May 4, 2016.
- Review the specific definitions of "cause," "good reason," and "change in control" in the new executive agreements to assess potential future cash outflows.
- Confirm the total number of outstanding shares (27,272,261) as of the May 2, 2016 record date.
- Check subsequent filings for any actual terminations or change in control events that would trigger the severance provisions outlined herein.